Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma - PubMed (original) (raw)
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma
Burkhard H A von Rahden et al. Cancer Res. 2005.
Abstract
Cyclooxygenases (COX), especially COX-2, are considered to be involved in carcinogenesis. Our study was initiated to test whether expression of COX isoforms (COX-1 and COX-2) is linked to expression of potent inducers of angiogenesis [vascular endothelial growth factor (VEGF)-A] and lymphangiogenesis (VEGF-C) in esophageal adenocarcinoma. One hundred twenty-three esophageal adenocarcinomas were investigated by means of quantitative reverse transcription-PCR for expression of COX-1, COX-2, VEGF-A, and VEGF-C. Additionally, COX-2 protein expression was determined using immunohistochemistry. Three esophageal cancer cell lines (OE-33, OSC-1, and OSC-2) were treated with COX-inhibiting substances (diclofenac, rofecoxib, and SC-560) and the effect on expression of the four genes was determined. COX-2 protein expression was found in all carcinomas under analysis. RNA expression levels of COX-1 and COX-2 varied markedly in carcinoma tissues and correlated significantly with each other (P < 0.001, r = 0.726). Furthermore, COX expression correlated with expression of VEGF-A (COX-1: P < 0.001, r = 0.753; COX-2: P < 0.001, r = 0.764) and VEGF-C (COX-1: P < 0.001, r = 0.778; COX-2: P < 0.001; r = 0.613). Exposure of esophageal cancer cell lines OE-33, OSC-1, and OSC-2 with three COX-inhibiting substances (diclofenac, rofecoxib, and SC-560) resulted in significantly reduced expression of VEGF-A and VEGF-C. In conclusion, our data suggest that both COX isoforms may be involved in the pathogenesis of esophageal adenocarcinoma, as they are linked to the expression of important modulators of angiogenesis (VEGF-A) and lymphangiogenesis (VEGF-C).
Similar articles
- Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Souza RF, et al. Cancer Res. 2000 Oct 15;60(20):5767-72. Cancer Res. 2000. PMID: 11059772 - Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, Chung SC, Sung JJ. Leung WK, et al. Int J Oncol. 2003 Nov;23(5):1317-22. Int J Oncol. 2003. PMID: 14532971 - Vascular endothelial growth factor in esophageal cancer.
Kleespies A, Guba M, Jauch KW, Bruns CJ. Kleespies A, et al. J Surg Oncol. 2004 Aug 1;87(2):95-104. doi: 10.1002/jso.20070. J Surg Oncol. 2004. PMID: 15282704 Review. - Cyclooxygenase as a target in lung cancer.
Brown JR, DuBois RN. Brown JR, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4266s-4269s. doi: 10.1158/1078-0432.CCR-040014. Clin Cancer Res. 2004. PMID: 15217972 Review.
Cited by
- Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Esquivias P, Morandeira A, Escartín A, Cebrián C, Santander S, Esteva F, García-González MA, Ortego J, Lanas A, Piazuelo E. Esquivias P, et al. World J Gastroenterol. 2012 Sep 21;18(35):4866-74. doi: 10.3748/wjg.v18.i35.4866. World J Gastroenterol. 2012. PMID: 23002358 Free PMC article. - Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.
Le CP, Karnezis T, Achen MG, Stacker SA, Sloan EK. Le CP, et al. Best Pract Res Clin Anaesthesiol. 2013 Dec;27(4):409-25. doi: 10.1016/j.bpa.2013.10.008. Epub 2013 Oct 15. Best Pract Res Clin Anaesthesiol. 2013. PMID: 24267548 Free PMC article. Review. - Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
Baryawno N, Sveinbjörnsson B, Eksborg S, Orrego A, Segerström L, Oqvist CO, Holm S, Gustavsson B, Kågedal B, Kogner P, Johnsen JI. Baryawno N, et al. Neuro Oncol. 2008 Oct;10(5):661-74. doi: 10.1215/15228517-2008-035. Epub 2008 Aug 20. Neuro Oncol. 2008. PMID: 18715952 Free PMC article. - Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.
Naini BV, Souza RF, Odze RD. Naini BV, et al. Am J Surg Pathol. 2016 May;40(5):e45-66. doi: 10.1097/PAS.0000000000000598. Am J Surg Pathol. 2016. PMID: 26813745 Free PMC article. Review. - A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, Zalcberg JR. Dawson SJ, et al. Invest New Drugs. 2007 Apr;25(2):123-9. doi: 10.1007/s10637-006-9016-5. Epub 2006 Oct 20. Invest New Drugs. 2007. PMID: 17053988 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials